Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Neoantigen Targeted Therapies Global Market Report 2025
Download Free Sample Buy Now
Global Neoantigen Targeted Therapies Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Neoantigen Targeted Therapies Global Market Report 2025

By Type (Monotherapy, Combination Therapy), By Immunotherapy Type (DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies), By Target Disease Indication (Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer), By Route of Administration (Intradermal, Intravenous, Subcutaneous), By Application (Medical Research Institution, Hospital, and Clinic, Other Applications) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Neoantigen Targeted Therapies Market Overview

• Neoantigen Targeted Therapies market size has reached to $3.4 billion in 2024

• Expected to grow to $15.93 billion in 2029 at a compound annual growth rate (CAGR) of 35.7%

• Growth Driver: Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market

• Market Trend: Strategic Partnerships Drive Advancements In Personalized Neoantigen Targeted Cancer Therapies

• North America was the largest region in 2024.

What Is Covered Under Neoantigen Targeted Therapies Market?

Neoantigen-targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body's immune system to recognize and attack cancer cells specifically by targeting these neoantigens.

The main types of neoantigens targeted therapies are monotherapy and combination therapy. The term monotherapy refers to a medical approach to treating a problem or disease that uses only one medicine or therapy. The various immunotherapy types include DNA or RNA-based vaccines, protein-based vaccines, Dendritic Cell Vaccines, and TIL-based therapies that target various disease indications such as colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. The various routes of administration include intradermal, intravenous, and subcutaneous, and the various applications include medical research institutions, hospitals, clinics, and others.

Neoantigen Targeted Therapies Market Size and growth rate 2025 to 2029: Graph

What Is The Neoantigen Targeted Therapies Market Size 2025 And Growth Rate?

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $3.4 billion in 2024 to $4.71 billion in 2025 at a compound annual growth rate (CAGR) of 38.3%. The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements

What Is The Neoantigen Targeted Therapies Market Growth Forecast?

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $15.93 billion in 2029 at a compound annual growth rate (CAGR) of 35.7%. The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models.

The forecast of 35.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of personalized cancer vaccines and sequencing reagents sourced from Switzerland and Japan, thereby delaying precision oncology advancements and elevating immunotherapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Neoantigen Targeted Therapies Market Segmented?

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Is Driving The Neoantigen Targeted Therapies Market? Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market

The increasing incidence of cancer cases is expected to propel the growth of the neoantigen targeted therapies market going forward. The incidence of cancer refers to the number of new cases of cancer in a specific population for a given period. Neoantigen-targeted therapies are often used in combination to treat different types of cancer. For instance, the American Cancer Society (ACS), a US-based voluntary health organization, in 2022, the United States had 1.9 million new cancer cases, representing a significant increase compared to previous years. Furthermore, in 2022, in the US, approximately 609,360 deaths were attributed to cancer, emphasizing the profound severity and impact of this disease on individuals and their families. Therefore, the increasing incidence of cancer cases is driving the growth of the neoantigen targeted therapies industry.

What Is Driving The Neoantigen Targeted Therapies Market? Surge Of Precision Oncology Propels Growth In The Neoantigen Targeted Therapies Market

The rising precision oncology is expected to propel the growth of the neoantigen targeted therapies market going forward. Precision oncology is an approach to cancer treatment that utilizes detailed genetic and molecular information about a patient's tumor to guide the selection of targeted therapies. Precision oncology uses neoantigen-targeted therapies by leveraging advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. The utilization of neoantigen-targeted therapies in precision oncology reflects a strategy to address the specific genetic makeup of each patient's tumor, offering a more personalized and effective treatment option. For instance, in March 2024, according to the Precision Oncology Clinical Trials & Statistics 2024 report published by Novotech, an Australia-based full-service clinical contract research organization involved in the development of innovative therapeutics across all phases, by November 2023, twelve treatments had received FDA approval for specific biomarker-selected indications, with six of these also included in the NCCN guidelines. By the year's end, 43% of the 217 FDA-approved oncology therapies were classified as precision oncology, and 78 of these therapies featured DNA or NGS-detectable biomarkers, highlighting the growing prominence of biomarker-driven treatments in cancer care. Therefore, rising precision oncology is driving the growth of the neoantigen-targeted therapies market.

Who Are The Major Players In The Global Neoantigen Targeted Therapies Market?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

What Are The Key Trends Of The Global Neoantigen Targeted Therapies Market? Strategic Partnerships Drive Advancements In Personalized Neoantigen Targeted Cancer Therapies

Major companies operating in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize cancer therapies to overcome the challenges of existing immunotherapy in the treatment of solid tumors. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in January 2023, BioNTech SE, a Germany-based biotechnology company partnered with the Government of the United Kingdom, a UK-based organization to advance personalized mRNA cancer immunotherapies. This collaboration aims to deliver tailored treatments to as many as 10,000 patients by 2030 and covers several critical areas, including the development of cancer immunotherapies, research on infectious disease vaccines, and the creation of a research and development hub in Cambridge. The initiative will leverage the UK’s clinical trial infrastructure and health data resources to improve patient recruitment and select trial sites for BioNTech’s mRNA treatments. The company plans to initiate its first clinical trials in the UK later this year, focusing on cancer vaccines that could potentially integrate into standard treatment protocols if proven effective.

What Are The Key Trends Of The Global Neoantigen Targeted Therapies Market? Strategic Partnerships In Neoantigen Targeted Therapies To Personalize Cancer Treatment And Enhance Immunotherapy Effectiveness

Major companies operating in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs to overcome the challenges of existing immunotherapy in the treatment of solid tumors. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company collaborated with Merck & Co., Inc. a US-based pharmaceutical company that launched mRNA-4157 (V940). It is an investigational individualized neoantigen therapy (INT) designed to generate a tailored antitumor immune response based on the unique mutational signature of a patient's tumor. mRNA-4157 (V940) works by encoding up to 34 neoantigens to stimulate T cell responses, enhancing the body’s ability to target and destroy tumor cells when combined with Merck’s immunotherapy KEYTRUDA. This combination aims to improve recurrence-free survival in patients with high-risk resected melanoma.

Need data on a specific region in this market?
Request Regional Data

Neoantigen Targeted Therapies Market Merger And Acquisition: Astrazeneca's Strategic Acquisition Of Neogene Therapeutics To Boost TCR Therapy Development

In January 2023, AstraZeneca plc, a UK-based pharmaceutical industry company acquired Neogene Therapeutics Inc. for $200 million. This acquisition aims to bolster AstraZeneca’s oncology portfolio, focusing on the development of transformative T-cell receptor (TCR) therapies targeting neoantigens in solid tumors. Neogene's expertise in next-generation TCR-T therapies is expected to complement AstraZeneca's existing capabilities in the oncology space, enabling the company to further its advancements in cancer treatments. Neogene Therapeutics Inc. is a US-based biotechnology company that provides neoantigen-targeted therapies.

Regional Outlook For The Global Neoantigen Targeted Therapies Market

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neoantigen Targeted Therapies Industry?

The neoantigen targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Neoantigen Targeted Therapies Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $4.71 billion
Revenue Forecast In 2034 $15.93 billion
Growth Rate CAGR of 35.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications Subsegments: 1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Neoantigen Targeted Therapies Market Characteristics

3. Neoantigen Targeted Therapies Market Trends And Strategies

4. Neoantigen Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neoantigen Targeted Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global Neoantigen Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Neoantigen Targeted Therapies Market Growth Rate Analysis

5.4. Global Neoantigen Targeted Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Neoantigen Targeted Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Neoantigen Targeted Therapies Total Addressable Market (TAM)

6. Neoantigen Targeted Therapies Market Segmentation

6.1. Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy

Combination Therapy

6.2. Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

DNA Or RNA-Based Vaccines

Protein-Based Vaccines

Dendritic Cell Vaccines

TIL-Based Therapies

6.3. Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Colorectal Cancer

Renal Cell Carcinoma

Non-Small Cell Lung Cancer

Bone Cancer

Gynecological Cancer

6.4. Global Neoantigen Targeted Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intradermal

Intravenous

Subcutaneous

6.5. Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Medical Research Institution

Hospital And Clinic

Other Applications

6.6. Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Individual Neoantigen-Targeted Treatments

6.7. Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Neoantigen-Targeted Therapies Combined With Other Immunotherapies

Neoantigen-Targeted Therapies Combined With Chemotherapy

Neoantigen-Targeted Therapies Combined With Targeted Therapies

7. Neoantigen Targeted Therapies Market Regional And Country Analysis

7.1. Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neoantigen Targeted Therapies Market

8.1. Asia-Pacific Neoantigen Targeted Therapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neoantigen Targeted Therapies Market

9.1. China Neoantigen Targeted Therapies Market Overview

9.2. China Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neoantigen Targeted Therapies Market

10.1. India Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neoantigen Targeted Therapies Market

11.1. Japan Neoantigen Targeted Therapies Market Overview

11.2. Japan Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neoantigen Targeted Therapies Market

12.1. Australia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neoantigen Targeted Therapies Market

13.1. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neoantigen Targeted Therapies Market

14.1. South Korea Neoantigen Targeted Therapies Market Overview

14.2. South Korea Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neoantigen Targeted Therapies Market

15.1. Western Europe Neoantigen Targeted Therapies Market Overview

15.2. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neoantigen Targeted Therapies Market

16.1. UK Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neoantigen Targeted Therapies Market

17.1. Germany Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neoantigen Targeted Therapies Market

18.1. France Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neoantigen Targeted Therapies Market

19.1. Italy Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neoantigen Targeted Therapies Market

20.1. Spain Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neoantigen Targeted Therapies Market

21.1. Eastern Europe Neoantigen Targeted Therapies Market Overview

21.2. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neoantigen Targeted Therapies Market

22.1. Russia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neoantigen Targeted Therapies Market

23.1. North America Neoantigen Targeted Therapies Market Overview

23.2. North America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neoantigen Targeted Therapies Market

24.1. USA Neoantigen Targeted Therapies Market Overview

24.2. USA Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neoantigen Targeted Therapies Market

25.1. Canada Neoantigen Targeted Therapies Market Overview

25.2. Canada Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neoantigen Targeted Therapies Market

26.1. South America Neoantigen Targeted Therapies Market Overview

26.2. South America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neoantigen Targeted Therapies Market

27.1. Brazil Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neoantigen Targeted Therapies Market

28.1. Middle East Neoantigen Targeted Therapies Market Overview

28.2. Middle East Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neoantigen Targeted Therapies Market

29.1. Africa Neoantigen Targeted Therapies Market Overview

29.2. Africa Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neoantigen Targeted Therapies Market Competitive Landscape And Company Profiles

30.1. Neoantigen Targeted Therapies Market Competitive Landscape

30.2. Neoantigen Targeted Therapies Market Company Profiles

30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Kite Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neoantigen Targeted Therapies Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.

31.2. Amgen Inc.

31.3. Moderna Inc.

31.4. BioNTech SE

31.5. Bavarian Nordic Inc.

31.6. Advaxis Inc.

31.7. Immatics NV

31.8. Precision Biologics Inc.

31.9. Iovance Biotherapeutics Inc.

31.10. Agenus Inc.

31.11. Achilles Therapeutics Plc

31.12. Medigene AG

31.13. Gritstone Bio Inc.

31.14. SQZ Biotechnologies Company

31.15. Aduro BioTech Inc.

32. Global Neoantigen Targeted Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neoantigen Targeted Therapies Market

34. Recent Developments In The Neoantigen Targeted Therapies Market

35. Neoantigen Targeted Therapies Market High Potential Countries, Segments and Strategies

35.1 Neoantigen Targeted Therapies Market In 2029 - Countries Offering Most New Opportunities

35.2 Neoantigen Targeted Therapies Market In 2029 - Segments Offering Most New Opportunities

35.3 Neoantigen Targeted Therapies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Neoantigen Targeted Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: F. Hoffmann-La Roche AG Financial Performance
  • Table 79: Merck and Co. Inc. Financial Performance
  • Table 80: Bristol Myers Squibb Company Financial Performance
  • Table 81: Eli Lilly and Company Financial Performance
  • Table 82: Kite Pharma Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Neoantigen Targeted Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: F. Hoffmann-La Roche AG Financial Performance
  • Figure 79: Merck and Co. Inc. Financial Performance
  • Figure 80: Bristol Myers Squibb Company Financial Performance
  • Figure 81: Eli Lilly and Company Financial Performance
  • Figure 82: Kite Pharma Inc. Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Read More About Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

RNA Targeting Small Molecules Therapeutics Global Market Report 2025 – By Offering (mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Ta...

View Report

Intratumoral Cancer Therapies Global Market Report 2025 – By Technology (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines ), By Applicati...

View Report

Gene Therapy Global Market Report 2025 – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis, Neurologi...

View Report

Neoantigen Targeted Therapies Global Market Report 2025 – By Type (Monotherapy, Combination Therapy), By Immunotherapy Type (DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies...

View Report

Targeted Therapy Global Market Report 2025 – By Type (Small Molecule Medicines, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Breast Cancer, ...

View Report

Anti-Neoplastic Agents Global Market Report 2025 – By Type (Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous), By Disease Type (Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Can...

View Report

Leukemia Therapeutics Global Market Report 2025 – By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments), By Type Of Leukemia (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymp...

View Report

Frequently Asked Questions

Neoantigen-targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body's immune system to recognize and attack cancer cells specifically by targeting these neoantigens. For further insights on this market, request a sample here

The market major growth driver - Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market. For further insights on this market, request a sample here

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $3.4 billion in 2024 to $4.71 billion in 2025 at a compound annual growth rate (CAGR) of 38.3%. The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements. The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to " $15.93 billion in 2029 at a compound annual growth rate (CAGR) of 35.7%. The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models. For further insights on this market, request a sample here

The neoantigen targeted therapiesmarket covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies For further insights on this market, request a sample here

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc. . For further insights on this market, request a sample here.

Major trends in this market include Strategic Partnerships Drive Advancements In Personalized Neoantigen Targeted Cancer Therapies. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Neoantigen Targeted Therapies Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon